Haematological malignancies are a type of cancer that affects the blood, lymph nodes and bone marrow. These types of cancers have numerous forms of lymphoma, leukaemia and myeloma. Haematological malignancies constituted 9% of all newly diagnosed malignancies in the United States in 2011, with data showing lymphomas as more prevalent than leukaemia’s or myeloma. Apart from acute lymphocytic leukaemia and Hodgkin’s lymphoma, these types of malignancy are usually associated with increasing age. Hence, considering the aging population across the globe, this class of malignancy is likely to become more prevalent.
Browse more detail information about Haematological Cancers market:
Broadly, there are 1,207 products that are in active development in the haematological cancer therapy area. The indications included in this disease group are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Haematological cancer has more number of active pipeline products than the respiratory and cardiovascular therapy areas, which indicate how active this disease cluster is in terms of product development.
Get a PDF Sample of Haematological Cancers market:
Scope Haematological Cancers market:
The haematological cancers industry is characterized by commercially successful therapies.
Haematological cancers clinical trials have an overall attrition rate of 70.3%.
The pipeline contains a wide range of molecule types and molecular targets, with focuss on targeted therapies, as opposed to chemotherapeutic agents.
The haematological cancers market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5%.
Big pharma holds a notable presence in the market.
Get Discount on Haematological Cancers market:
Reasons to buy Haematological Cancers market:
This report will allow you to:
Have any query? ask our http://www.absolutereports.com/enquiry/pre-order-enquiry/10186813
List of Figures, Tables and Charts Available in Global Hematological Cancers Market to 2022 – Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market
1.1 List of Tables
Table 1: Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, 2016-2020
Table 2: Hematological Cancers Therapeutics Market, Global, Lymphoma, Prognostic Factors, 2016-2020
Table 3: Hematological Cancers Therapeutics Market, Global, Multiple Myeloma, Prognostic Factors, 2016-2020
Table 4: Hematological Cancers Therapeutics Market, Global, Commonly Used Chemo-Regimens, 2016-2020
Table 5: Hematological Cancers Therapeutics Market, Global, Approved Indications for Rituxan, 2016-2020
Table 6: Hematological Cancers Therapeutics Market, Global, Approved Indications for Gleevec, 2016-2020
Table 7: Hematological Cancers Therapeutics Market, Global, Approved Indications for Revlimid, 2016-2020
Table 8: Hematological Cancers Therapeutics Market, Global, Approved Indications for Velcade, 2016-2020
Table 9: Hematological Cancers Therapeutics Market, Global, Approved Indications for Sprycel, 2016-2020
Table 10: Hematological Cancers Therapeutics Market, Global, Approved Indications for Tasigna, 2016-2020
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.